Compounding Pharmacies Market Huge Growth in Future Scope 2021-2028 | Central Admixture Pharmacy Services, Fagron, Fresenius Kabi AG, PharMEDium Services, LLC

Global Compounding Pharmacies Market to Surpass US$ 13,304.8 Million by 2027, Owing to Shortage of Essential Medicines for the Treatment of Critical Diseases

Compounding pharmacy involves combining or mixes of APIs to develop a customized drug for various diseases. The global market for compounding pharmacies is driven by shortage of essential medicines for the treatment of critical diseases. For instance, according to a report of the U.S. Food and Drug Administration (FDA): Drug Shortages: Root Causes and Potential Solutions 2019, 56% of hospitals reported they had changed patient care or delayed therapy in light of drug shortages and 36.6% said they had rescheduled non-urgent or emergent procedures.

However, use of compounded pharmacy drugs in routine surgery may lead to several side effects including loss of eyesight, which is expected to hamper growth of the global compounded pharmacies market. Moreover, availability of FDA-approved drugs is also expected to limit growth of the market. For instance, in December 2019, Eton Pharmaceuticals, Inc. commercialized Biorphen, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. The availability of Biorphen reduces the need for hospitals to rely on compounders to provide unapproved compounded phenylephrine.

To Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/3199

Among products, the topical medication segment in expected to witness significant growth in the global compounding pharmacies market over the forecast period. This is attributed to increasing demand for topical pain management drugs. The segment was valued at US$ 3,335.4 Mn in 2018 and is expected to reach US$ 5,784.9 Mn by 2025 at a CAGR of 5.6 %.

Among therapeutic areas, the pain management segment in expected to witness significant growth in the global compounding pharmacies market over the forecast period. This is attributed to increasing incidence of chronic and acute pain. The segment was valued at US$ 4,980.2 Mn in 2014 and is expected to reach US$ 7,894.4 Mn by 2027 at a CAGR of 4.7 %.

Regulations:

In the U.S., a pharmacy can register as an “outsourcing facility” under the Drug Quality and Security Act (2013) Section 503B only if:

• It complies with cGMP requirements
• Inspected and approved by the U.S. FDA
• Follows a legal reporting schedule of adverse events to the U.S. FDA

Such a facility can perform legal sterile compounding of drugs and interstate drug shipments. Moreover, the compounding pharmacies regulations in the U.S. are evolving after the formation of Pharmacy Compounding Advisory Committee (PCAC). The PCAC advices on scientific, technical, and medical issues that are related to drug compounding under Section 503A and Section 503B of the Food, Drug, and Cosmetic Act (FDCA).

For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/3199

Key Takeaways:

• Shortage of essential medicines for the treatment of critical diseases is expected to propel growth of the global compounded pharmacies market

• Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in April 2018, Fagron acquired Humco, a developer, manufacturer and supplier of patented delivery vehicles and branded pharmaceutical products in the U.S.

• Key players in the market are also focused on adopting partnership strategies to enhance their product portfolio. For instance, in July 2019, Guardian Pharmacy Services partnered with TruCare LTC Pharmacy. The partnership expands Guardian’s Midwest footprint and marks its first venture into Michigan.

• Major players operating in the global compounding pharmacies market include, Central Admixture Pharmacy Services, Fagron, Fresenius Kabi AG, PharMEDium Services, LLC, Institutional Pharmacy Solutions, Cantrell Drug Company, Triangle Compounding Pharmacies, and Lorraine’s Pharmacy.

To Direct Purchase this Premium Research Report – https://www.coherentmarketinsights.com/insight/buy-now/3199

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.